Do patients with inflammatory bowel disease want genetic testing?

Inflammatory Bowel Diseases

Volumn 12, Issue 6, 2006, Pages 497-502

  Konda, Vani ^a   Huo, Dezheng ^a   Hermes, Gretchen ^a   Liu, Michael ^a   Patel, Roshan ^a   Rubin, David T ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MC 4076 ^*  (United States)

Author keywords

Genetic testing; Inflammatory bowel disease

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENTERITIS; FAMILY; FEMALE; GENETIC ANALYSIS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; VALIDATION PROCESS;

ADULT; ATTITUDE TO HEALTH; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; UNCERTAINTY;

EID: 33745227415     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/00054725-200606000-00009     Document Type: Article

References (15)

1. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001;357:1925-1928.
2. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
3. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
4. Bayless TM, Tokayer AZ, Polito JM 2nd, et al. Crohn's disease: concordance for site and clinical type in affected family members-potential hereditary influences. Gastroenterology. 1996;111:573-579.
5. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002;122:867-874.
6. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002;122:854-866.
7. Lesage S, Zouali H, Cézard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845-857.
8. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn's disease. Nat Genet. 2004;36:471-475.
9. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804-810.
10. Irvine EJ. Quality of life: rationale and methods for developing a disease-specific instrument for inflammatory bowel disease. Scand J Gastroenterol Suppl. 1993;199:22-27.
11. Irvine EJ. Quality of life: measurement in inflammatory bowel disease. Scand J Gastroenterol Suppl. 1993;199:36-39.
12. Irvine EJ, Feagan B, Rochon J, et al. For the Canadian Crohn's Relapse Prevention Trial Study Group. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology. 1994;106:287-296.
13. Froberg DB, Kane RL. Methodology for measuring health-state preferences, II: scaling methods. J Clin Epidemiol. 1989;42:459-471.
14. Kirsner JB. Historical origins of current IBD concepts. World J Gastroenterol. 2001;7:175-184.
15. Polito JM 2nd, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996;111:580-556.